Clinical Trial

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Study acronym: ORACLE
Recruiting
View on ClinicalTrials.gov →
Summary
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for recurrence detection and explore its value in a healthcare environment subject to cost containment.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-09-17; most recent amendment 2025-08-18.
Trial Details
NCT Number NCT05059444
Lead Sponsor Guardant Health, Inc.
Conditions Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer, Invasive Breast Carcinoma, Cutaneous Melanoma, Esophageal Carcinoma, Gastroesophageal Junction Carcinoma +8 more
Enrollment 2,020 participants
Start Date 2021-09-07
Primary Completion 2029-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2025-08-22